|
DE3413608A1
(de)
*
|
1984-04-11 |
1985-10-24 |
Hoechst Ag, 6230 Frankfurt |
Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
|
|
US5137874A
(en)
*
|
1985-07-29 |
1992-08-11 |
American Cyanamid Co. |
Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
|
|
IL79134A
(en)
*
|
1985-07-29 |
1991-06-10 |
American Cyanamid Co |
Continuous release peptide implants for parenteral administration
|
|
US4761289A
(en)
*
|
1986-10-10 |
1988-08-02 |
International Minerals & Chemical Corp. |
Sustained release implant and method for preparing same
|
|
DE3855869T2
(de)
|
1987-02-20 |
1997-10-02 |
Genentech Inc |
Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
|
|
DE3712095A1
(de)
*
|
1987-04-10 |
1988-10-20 |
Lentia Gmbh |
Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
|
|
DE3811231A1
(de)
*
|
1988-04-02 |
1989-10-12 |
Beiersdorf Ag |
Chirurgische implantate
|
|
EP0423484B1
(de)
*
|
1989-10-16 |
1993-11-03 |
PCD-Polymere Gesellschaft m.b.H. |
Pressling mit retardierter Wirkstofffreisetzung
|
|
WO1993015722A1
(en)
*
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
|
JP2651320B2
(ja)
*
|
1992-07-16 |
1997-09-10 |
田辺製薬株式会社 |
徐放性マイクロスフェア製剤の製造方法
|
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
CA2265972A1
(en)
*
|
1996-09-16 |
1998-03-26 |
Philip D. Acott |
Use of igf-i for the treatment of polycystic kidney disease and related indications
|
|
AU731553B2
(en)
|
1996-10-25 |
2001-04-05 |
Human Genome Sciences, Inc. |
Neutrokine alpha
|
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
|
CA2291221A1
(en)
|
1997-05-30 |
1998-12-03 |
Human Genome Sciences, Inc. |
32 human secreted proteins
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
WO1999014240A1
(en)
|
1997-09-17 |
1999-03-25 |
Human Genome Sciences, Inc. |
Interleukin-17 receptor-like protein
|
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
|
DK2016951T3
(da)
|
1998-03-17 |
2012-09-24 |
Genentech Inc |
VEGF- og BMP1-homologe polypeptider
|
|
EP1982990A1
(en)
|
1998-03-19 |
2008-10-22 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
|
CN1309734C
(zh)
|
1999-02-03 |
2007-04-11 |
安姆根有限公司 |
与免疫应答有关的新颖多肽
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
AU3770800A
(en)
|
1999-03-26 |
2000-10-16 |
Amgen, Inc. |
Beta secretase genes and polypeptides
|
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
|
WO2001000832A1
(en)
|
1999-06-28 |
2001-01-04 |
Genentech, Inc. |
Methods for making apo-2 ligand using divalent metal ions
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
|
CA2747325A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
CA2709771A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
EP1294879B1
(en)
|
2000-06-28 |
2008-12-31 |
Amgen Inc. |
Thymic stromal lymphopoietin receptor molecules and uses thereof
|
|
AU1796902A
(en)
|
2000-11-28 |
2002-06-11 |
Amgen Inc |
Novel polypeptides involved in immune response
|
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
|
RS54274B1
(en)
|
2001-06-26 |
2016-02-29 |
Amgen Fremont Inc. |
Opgl antibodies
|
|
JP4399260B2
(ja)
|
2001-08-24 |
2010-01-13 |
ニューレン ファーマシューティカルズ リミテッド |
神経再生ペプチドおよび脳損傷治療におけるその使用方法
|
|
MXPA04001720A
(es)
|
2001-08-29 |
2004-05-31 |
Genentech Inc |
Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
|
|
US7459432B2
(en)
|
2001-09-24 |
2008-12-02 |
Imperial College Innovations Ltd. |
Modification of feeding behavior
|
|
CA2461292A1
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
|
MXPA04003291A
(es)
|
2001-10-12 |
2004-07-23 |
Schering Corp |
Uso de anticuerpos biespecificos para ragular respuestas inmunes.
|
|
EP1450847B1
(en)
|
2001-11-13 |
2010-09-29 |
Genentech, Inc. |
APO2 ligand/ TRAIL formulations and uses thereof
|
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
JP4733922B2
(ja)
|
2002-01-10 |
2011-07-27 |
インペリアル・イノベ−ションズ・リミテッド |
摂食行動の修正
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
|
US7718776B2
(en)
|
2002-04-05 |
2010-05-18 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
|
JP4386741B2
(ja)
|
2002-04-15 |
2009-12-16 |
中外製薬株式会社 |
ｓｃＤｂライブラリーの作成方法
|
|
EP1505148B1
(en)
|
2002-04-26 |
2009-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening for agonistic antibodies
|
|
WO2003099320A1
(en)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
AU2003247609A1
(en)
|
2002-06-24 |
2004-01-06 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
|
CA2497884C
(en)
|
2002-09-06 |
2013-10-22 |
Brian Varnum |
Therapeutic human anti-il-1r1 monoclonal antibody
|
|
US9809654B2
(en)
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
|
US7335743B2
(en)
|
2002-10-16 |
2008-02-26 |
Amgen Inc. |
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
|
|
ATE472556T1
(de)
|
2002-12-02 |
2010-07-15 |
Amgen Fremont Inc |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
|
EP1578782A4
(en)
|
2002-12-30 |
2007-09-12 |
Amgen Inc |
COSTIMULATING FACTORIAL THERAPY
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
US20050069541A1
(en)
|
2003-01-24 |
2005-03-31 |
Karlik Stephen J. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
|
KR101118340B1
(ko)
|
2003-03-12 |
2012-04-12 |
제넨테크, 인크. |
조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의용도
|
|
EP3000886A1
(en)
|
2003-03-19 |
2016-03-30 |
Amgen Fremont Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
|
WO2004103313A2
(en)
|
2003-05-20 |
2004-12-02 |
The American National Red Cross |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tpa) and tpa inhibitors useful therein
|
|
CN104059147A
(zh)
|
2003-06-27 |
2014-09-24 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
|
PT1648998E
(pt)
|
2003-07-18 |
2014-11-04 |
Amgen Inc |
Agentes de ligação específica ao factor de crescimento do hepatócito
|
|
ES2373783T3
(es)
|
2003-09-12 |
2012-02-08 |
Tercica, Inc. |
Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (igf-1).
|
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
CA2543484C
(en)
|
2003-10-27 |
2014-02-04 |
Amgen Inc. |
Modulation of immune response to an immunogen with ctla-4 and tnfbp
|
|
CA2553034A1
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
|
US20050255118A1
(en)
|
2004-02-06 |
2005-11-17 |
Nancy Wehner |
Methods and composition for treating tumors and metastatic disease
|
|
MXPA06010673A
(es)
|
2004-03-19 |
2007-06-20 |
Amgen Inc |
Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
|
|
JP4705026B2
(ja)
|
2004-03-19 |
2011-06-22 |
ジェノミディア株式会社 |
血管内皮増殖促進遺伝子
|
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
|
CN106434833A
(zh)
|
2004-05-23 |
2017-02-22 |
杰勒德·M·豪斯 |
Theramutein调节剂
|
|
EP2298335B1
(en)
|
2004-05-25 |
2014-09-03 |
Stryker Corporation |
Use of OP-1 for treating cartilage defects
|
|
CA2568952C
(en)
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
|
US20100098663A2
(en)
|
2004-06-22 |
2010-04-22 |
The Board Of Trustees Of The University Of Illinois |
Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA
|
|
PT1776136E
(pt)
|
2004-06-24 |
2012-12-05 |
Biogen Idec Inc |
Tratamento de estados que envolvem desmielinização
|
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
|
EP1789070B1
(en)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Taj in neuronal function
|
|
AU2005267722B2
(en)
|
2004-08-04 |
2009-10-08 |
Amgen Inc. |
Antibodies to Dkk-1
|
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
|
WO2006037182A1
(en)
|
2004-10-06 |
2006-04-13 |
Agri-Biotech Pty Ltd |
Antibody production method
|
|
US8034345B2
(en)
|
2004-10-15 |
2011-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-PCI antibody for regulating liver regeneration/repair
|
|
MX2007005866A
(es)
|
2004-11-17 |
2007-11-12 |
Amgen Inc |
Anticuerpos monoclonales totalmente humanos para il-13.
|
|
EP1827446A4
(en)
|
2004-12-06 |
2011-01-12 |
Siga Technologies Inc |
SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND URETINS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS WITH ARENA VIRUSES
|
|
TW200635946A
(en)
|
2004-12-20 |
2006-10-16 |
Abgenix Inc |
Binding proteins specific for human matriptase
|
|
RS52036B
(en)
|
2004-12-21 |
2012-04-30 |
Medimmune Limited |
ANGIOPOETIN-2 ANTIBODIES AND ITS USES
|
|
EP1836314B1
(en)
|
2004-12-22 |
2012-01-25 |
Ambrx, Inc. |
Modified human growth hormone
|
|
CN104803865A
(zh)
|
2004-12-22 |
2015-07-29 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途
|
|
US7566772B2
(en)
|
2005-01-26 |
2009-07-28 |
Amgen Fremont Inc. |
Antibodies against interleukin-1β
|
|
PL1876236T3
(pl)
|
2005-04-08 |
2015-01-30 |
Chugai Pharmaceutical Co Ltd |
Przeciwciała zastępujące czynność czynnika krzepnięcia VIII
|
|
US20080009546A1
(en)
|
2005-05-06 |
2008-01-10 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
|
|
US7417072B2
(en)
|
2005-05-12 |
2008-08-26 |
Wisconsin Alumni Research Foundation |
Blockade of Pin1 prevents cytokine production by activated immune cells
|
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
|
WO2006132363A1
(ja)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
|
|
WO2006132341A1
(ja)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2部位特異的変異体
|
|
SG162788A1
(en)
|
2005-06-14 |
2010-07-29 |
Amgen Inc |
Self-buffering protein formulations
|
|
JP4931919B2
(ja)
|
2005-06-21 |
2012-05-16 |
ゾーマ テクノロジー リミテッド |
ＩＬ−１β結合抗体およびその断片
|
|
CN101495509B
(zh)
|
2005-07-08 |
2015-04-22 |
比奥根艾迪克Ma公司 |
Sp35抗体及其用途
|
|
AU2006270009A1
(en)
|
2005-07-18 |
2007-01-25 |
Amgen Inc. |
Human anti-B7RP1 neutralizing antibodies
|
|
US20100004156A1
(en)
|
2005-07-27 |
2010-01-07 |
Shalesh Kaushal |
Small Compounds That Correct Protein Misfolding and Uses Thereof
|
|
WO2007142667A2
(en)
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
|
CN101330929B
(zh)
|
2005-10-14 |
2014-03-05 |
学校法人福冈大学 |
胰岛移植中的移植胰岛障碍抑制剂
|
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
|
AU2006311828B2
(en)
|
2005-11-04 |
2013-07-11 |
Biogen Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
|
EP2548583A3
(en)
|
2005-11-10 |
2013-02-27 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
|
EP2338517A1
(en)
|
2005-11-14 |
2011-06-29 |
Ribomic Inc |
Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
|
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
|
CN101454461A
(zh)
|
2005-11-16 |
2009-06-10 |
Ambrx公司 |
包括非天然氨基酸的方法和组合物
|
|
EP1967209B1
(en)
|
2005-11-25 |
2012-06-06 |
Keio University |
Therapeutic agent for prostate cancer
|
|
NZ598421A
(en)
|
2005-12-02 |
2013-11-29 |
Biogen Idec Inc |
Treatment of Conditions Involving Demyelination
|
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
|
US8158588B2
(en)
|
2005-12-05 |
2012-04-17 |
Simon Delagrave |
Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
|
|
BRPI0619786A2
(pt)
|
2005-12-13 |
2011-10-18 |
Astrazeneca Ab |
proteìna de ligação especìfica, molécula de ácido nucleico, vetor, célula hospedeira, anticorpo monoclonal humano, método para determinar o nìvel de fator de crescimento tipo insulina-ii (igf-1i) e fator de crescimento tipo insulina i (igf-1) em uma amostra de paciente, uso da proteìna de ligação especìfica, e, conjugado
|
|
BRPI0619853A2
(pt)
|
2005-12-15 |
2016-08-23 |
Astrazeneca Ab |
combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
|
|
EP3363455A1
(en)
|
2005-12-30 |
2018-08-22 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
|
WO2007083644A1
(ja)
|
2006-01-17 |
2007-07-26 |
Dnavec Corporation |
新規タンパク質発現系
|
|
WO2007089601A2
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
|
EP3135298B1
(en)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutic agents for diseases involving choroidal neovascularization
|
|
WO2007116962A1
(ja)
|
2006-04-07 |
2007-10-18 |
Osaka University |
筋再生促進剤
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
EP2540310A1
(en)
|
2006-05-17 |
2013-01-02 |
Stryker Corporation |
Methods of treating cartilage defects using a soluble morphogenic protein complex
|
|
ES2429225T3
(es)
|
2006-05-17 |
2013-11-13 |
The Ludwig Institute For Cancer Research |
Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
|
|
EP2049570B1
(en)
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
|
UA100116C2
(ru)
|
2006-06-08 |
2012-11-26 |
Чугей Сейяку Кабусики Кайся |
Профилактика или лечение воспалительного заболевания
|
|
CA2657385A1
(en)
|
2006-07-13 |
2008-01-17 |
Naoki Kimura |
Cell death inducer
|
|
EP2574625B1
(en)
|
2006-07-21 |
2015-02-25 |
HuBit genomix, Inc. |
Remedy for renal disease
|
|
US7666423B2
(en)
|
2006-07-28 |
2010-02-23 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
WO2008019368A2
(en)
|
2006-08-07 |
2008-02-14 |
Teva Biopharmaceuticals Usa, Inc. |
Albumin-insulin fusion proteins
|
|
WO2008030558A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
|
RU2447449C2
(ru)
|
2006-11-14 |
2012-04-10 |
Дженентек, Инк. |
Модуляторы нейрональной регенерации
|
|
WO2008073300A2
(en)
|
2006-12-08 |
2008-06-19 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
RU2554747C9
(ru)
|
2006-12-20 |
2015-10-20 |
Ксома (Сша) Ллс |
Способы лечения il-1бета-зависимых заболеваний
|
|
GEP20125693B
(en)
|
2007-01-09 |
2012-11-26 |
Biogen Idec Inc |
Sp35 antibodies and usage thereof
|
|
CA2675625C
(en)
|
2007-01-23 |
2016-09-13 |
Shinshu University |
Chronic rejection inhibitor
|
|
MX2009008178A
(es)
|
2007-02-02 |
2009-10-26 |
Biogen Idec Inc |
Uso de semaforina 6a para promover la mielinizacion y la diferenciacion de oligodendrocitos.
|
|
WO2013106175A1
(en)
|
2011-12-19 |
2013-07-18 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
TWI454479B
(zh)
|
2007-03-06 |
2014-10-01 |
Amgen Inc |
變異之活動素受體多肽及其用途
|
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
|
ES2385114T3
(es)
|
2007-03-30 |
2012-07-18 |
Ambrx, Inc. |
Polipéptidos de FGF-21 modificados y sus usos
|
|
US20110065673A1
(en)
|
2007-05-11 |
2011-03-17 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor agonist
|
|
EP1995227A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disorders
|
|
EP1994927A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
|
|
MX2009013765A
(es)
|
2007-06-27 |
2010-02-01 |
Auckland Uniservices Ltd |
Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.
|
|
US20100129355A1
(en)
|
2007-07-26 |
2010-05-27 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
|
HUE037265T2
(hu)
|
2007-08-21 |
2018-08-28 |
Amgen Inc |
Humán c-fms antigént kötõ proteinek
|
|
EP4248976A3
(en)
|
2007-08-23 |
2024-04-10 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
|
EP2497783A3
(en)
|
2007-09-26 |
2013-04-17 |
U3 Pharma GmbH |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
US8529895B2
(en)
|
2007-10-02 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies
|
|
AU2008322523B2
(en)
|
2007-11-16 |
2013-10-10 |
The Rockefeller University |
Antibodies specific for the protofibril form of beta-amyloid protein
|
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
|
EP2236604B1
(en)
|
2007-12-05 |
2016-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10 antibody and use thereof
|
|
AU2008332276B2
(en)
|
2007-12-05 |
2014-02-27 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for pruritus
|
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
|
MX2010006823A
(es)
|
2007-12-20 |
2010-09-30 |
Xoma Technology Ltd |
Metodos para el tratamiento de la gota.
|
|
NZ586947A
(en)
|
2008-02-08 |
2012-11-30 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
CA2728243C
(en)
|
2008-06-05 |
2020-03-10 |
National Cancer Center |
Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
|
|
PL2307381T3
(pl)
|
2008-06-09 |
2021-07-05 |
Ludwig-Maximilians-Universität München |
Nowe leki do hamowania agregacji białek związanych z chorobami związanymi z agregacją białka i/lub chorobami neurodegeneracyjnymi
|
|
EP2307456B1
(en)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
|
CN106928339A
(zh)
|
2008-07-23 |
2017-07-07 |
Ambrx 公司 |
经修饰的牛g‑csf多肽和其用途
|
|
CN102149728B
(zh)
|
2008-09-10 |
2014-10-15 |
霍夫曼-拉罗奇有限公司 |
抑制眼部血管生成的方法
|
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
|
BRPI0919031A2
(pt)
|
2008-09-26 |
2014-09-23 |
Ambrx Inc |
Micro-organismos e vacinas dependentes de replicação através do uso de aminoácidos não naturais
|
|
CN107022020A
(zh)
|
2008-09-26 |
2017-08-08 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
|
AU2009303304A1
(en)
|
2008-10-10 |
2010-04-15 |
Anaphore, Inc. |
Polypeptides that bind TRAIL-RI and TRAIL-R2
|
|
UA105016C2
(uk)
|
2008-10-10 |
2014-04-10 |
Амген Інк. |
Fgf21 мутанти і їх застосування
|
|
MX2011004306A
(es)
|
2008-10-22 |
2011-07-28 |
Genentech Inc |
Modulacion de degeneracion de axones.
|
|
CN104371024A
(zh)
|
2008-11-26 |
2015-02-25 |
安姆根有限公司 |
激活素iib受体多肽的变异体及其用途
|
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
|
WO2010072684A1
(en)
|
2008-12-22 |
2010-07-01 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
|
CN102325875B
(zh)
|
2009-01-08 |
2018-04-10 |
阿尔伯爱因斯坦医学有限公司 |
具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
|
|
US20110294733A1
(en)
|
2009-01-20 |
2011-12-01 |
Hanall Biopharma Co., Ltd. |
Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
|
|
US20110014190A1
(en)
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
EA020118B1
(ru)
|
2009-02-13 |
2014-08-29 |
Новартис Аг |
Молекула нуклеиновой кислоты биосинтетического кластера, кодирующая нерибосомальные пептидсинтазы, и ее применение
|
|
AU2010218152B2
(en)
|
2009-02-27 |
2015-04-09 |
Siga Technologies, Inc. |
Thienopyridine derivatives for the treatment and prevention of Dengue virus infections
|
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
|
US9724337B2
(en)
|
2009-04-21 |
2017-08-08 |
University Of Kentucky Research Foundation |
AG-205 for the treatment of breast cancer
|
|
EP4353247A3
(en)
|
2009-05-05 |
2024-07-17 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
|
US20120052069A1
(en)
|
2009-05-05 |
2012-03-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
|
IN2012DN00352A
(da)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
|
MX2011013903A
(es)
|
2009-06-17 |
2012-05-08 |
Amgen Inc |
Polipeptidos quimericos y usos de los mismos.
|
|
NZ598127A
(en)
|
2009-07-31 |
2014-03-28 |
Shin Maeda |
Cancer metastasis inhibitor
|
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
WO2011046457A1
(en)
|
2009-10-16 |
2011-04-21 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
|
KR101278690B1
(ko)
|
2009-10-19 |
2013-06-24 |
한올바이오파마주식회사 |
변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
|
|
EP2490698A4
(en)
|
2009-10-22 |
2013-09-25 |
Hoffmann La Roche |
MODULATION OF THE AXONDEGENERATION
|
|
DK3202898T3
(da)
|
2009-11-02 |
2019-01-14 |
Univ Washington |
Terapeutiske nuclease-sammensætninger og fremgangsmåder
|
|
US20130123181A1
(en)
|
2009-11-13 |
2013-05-16 |
Kathleen Pratt |
Factor VIII T Cell Epitope Variants Having Reduced Immunogenicity
|
|
SMT202000195T1
(it)
|
2009-11-24 |
2020-05-08 |
Medimmune Ltd |
Agenti leganti direzionati contro b7-h1
|
|
WO2014121221A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an anti-activin-a compound to a subject
|
|
US8372952B2
(en)
|
2009-12-02 |
2013-02-12 |
Amgen Inc. |
Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
|
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
EP2805964A1
(en)
|
2009-12-21 |
2014-11-26 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
|
MX2012006980A
(es)
|
2009-12-21 |
2012-07-17 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos.
|
|
US20130053438A1
(en)
|
2010-01-19 |
2013-02-28 |
Universitat Innsbruck |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
|
EP2528938A4
(en)
|
2010-01-27 |
2013-10-23 |
Childrens Medical Center |
PROANGIOGENIC FRAGMENTS OF PROMININ-1 AND USES THEREOF
|
|
US8778416B2
(en)
|
2010-02-10 |
2014-07-15 |
Nayacure Therapeutics Ltd. |
Pharmaceutical compositions and methods for the treatment and prevention of cancer
|
|
US9233087B2
(en)
|
2010-02-19 |
2016-01-12 |
Siga Technologies, Inc |
Inhibitors and methods of inhibiting bacterial and viral pathogens
|
|
WO2011119906A1
(en)
|
2010-03-26 |
2011-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
|
|
JPWO2011118804A1
(ja)
|
2010-03-26 |
2013-07-04 |
国立大学法人徳島大学 |
新規抗ｃｄ９８抗体とその用途
|
|
WO2011130417A2
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
|
|
EP2561068A1
(en)
|
2010-04-19 |
2013-02-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
WO2011139595A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
|
|
WO2011139594A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Artificial bursa for intra-articular drug delivery
|
|
US9320756B2
(en)
|
2010-05-07 |
2016-04-26 |
Centre National De La Recherche Scientifique |
UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
|
|
EP2571987B1
(en)
|
2010-05-21 |
2017-03-01 |
Peptimed, Inc. |
Reagents for treating cancer
|
|
EP4115906A1
(en)
|
2010-05-28 |
2023-01-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
|
WO2011157819A2
(en)
|
2010-06-18 |
2011-12-22 |
Xiberscience Gmbh |
Peptides as active agents to stabilize biological barriers
|
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
|
PT2605789T
(pt)
|
2010-08-17 |
2019-09-03 |
Ambrx Inc |
Polipeptidos de relaxina modificados e suas utilizações
|
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
|
KR101886890B1
(ko)
|
2010-09-28 |
2018-08-08 |
세키스이가가쿠 고교가부시키가이샤 |
항인간 ｃｃｒ７ 항체, 하이브리도마, 핵산, 벡터, 세포, 의약 조성물 및 항체 고정화 담체
|
|
BR112013010136A2
(pt)
|
2010-10-25 |
2019-09-24 |
Univ Minnesota |
vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
|
|
TWI636993B
(zh)
|
2010-10-27 |
2018-10-01 |
安美基公司 |
Ｄｋｋ１抗體及使用方法
|
|
WO2012061443A2
(en)
|
2010-11-01 |
2012-05-10 |
NanoOncology, Inc. |
Compositions of a peptide-based system for cell-specific targeting
|
|
AU2011330184B2
(en)
|
2010-11-17 |
2016-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII
|
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
|
JP6033229B2
(ja)
|
2010-11-24 |
2016-11-30 |
レクシコン ファーマシューティカルズ インコーポレイテッド |
Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体
|
|
TWI807362B
(zh)
|
2010-11-30 |
2023-07-01 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
EP3287458B1
(en)
|
2010-11-30 |
2022-07-13 |
The Johns Hopkins University |
Hybrid cyclic libraries and screening thereof
|
|
US8754037B2
(en)
|
2010-12-23 |
2014-06-17 |
Hanall Biopharma Co., Ltd. |
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
|
US9708366B2
(en)
|
2011-01-27 |
2017-07-18 |
Neuren Pharmaceuticals Ltd. |
Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
|
|
AU2012223358A1
(en)
|
2011-03-01 |
2013-09-05 |
Amgen Inc. |
Sclerostin and DKK-1 bispecific binding agents
|
|
AU2012225248A1
(en)
|
2011-03-10 |
2013-09-19 |
Genentech, Inc. |
Treatment of disorders with altered vascular barrier function
|
|
KR20140027211A
(ko)
|
2011-04-04 |
2014-03-06 |
유니버시티 오브 아이오와 리써치 파운데이션 |
백신 면역원성의 개선 방법
|
|
WO2012138997A1
(en)
|
2011-04-07 |
2012-10-11 |
Amgen Inc. |
Novel egfr binding proteins
|
|
US10752664B2
(en)
|
2011-04-08 |
2020-08-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
|
PL2704737T3
(pl)
|
2011-04-29 |
2018-07-31 |
University Of Washington |
Terapeutyczne kompozycje nukleaz i sposoby
|
|
JP2014513128A
(ja)
|
2011-05-03 |
2014-05-29 |
ジェネンテック， インコーポレイテッド |
血管破壊剤とその使用
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
AU2012254160A1
(en)
|
2011-05-10 |
2013-11-21 |
Amgen Inc. |
Method of identifying compounds that specifically modulate the interaction of FGFR1 and beta-Klotho
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
WO2012174064A1
(en)
|
2011-06-14 |
2012-12-20 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
JP2014520123A
(ja)
|
2011-06-17 |
2014-08-21 |
アムジエン・インコーポレーテツド |
Ｃｌｅｃ−２を使用して代謝性障害を治療または改善させる方法
|
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
|
US9328386B2
(en)
|
2011-08-16 |
2016-05-03 |
Evotec (München) Gmbh |
Markers for susceptibility to an inhibitor of an Src-family kinase
|
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
|
EP3348575A1
(en)
|
2011-08-16 |
2018-07-18 |
Emory University |
Jaml specific binding agents, antibodies, and uses related thereto
|
|
CA2845357A1
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
|
JO3625B1
(ar)
|
2011-09-22 |
2020-08-27 |
Amgen Inc |
بروتينات رابطة للأنتيجين cd27l
|
|
US9006400B2
(en)
|
2011-09-26 |
2015-04-14 |
Novartis Ag |
Fibroblast growth factor-21-Fc fusion proteins
|
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
|
CA2850322C
(en)
|
2011-09-30 |
2023-10-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun （Shanghai）Science & Technology Limited |
Compositions and methods for treating heart failure
|
|
WO2013056255A1
(en)
|
2011-10-14 |
2013-04-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for inhibiting tumor cell proliferation
|
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
|
AU2012325341B2
(en)
|
2011-10-19 |
2017-01-05 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
CN104168922A
(zh)
|
2011-11-16 |
2014-11-26 |
安姆根有限公司 |
治疗表皮生长因子缺失突变体viii相关疾病的方法
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
CA2862807A1
(en)
|
2011-11-30 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
US10040749B2
(en)
|
2011-12-01 |
2018-08-07 |
Bikam Pharmaceuticals Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
|
CA2858572C
(en)
|
2011-12-08 |
2023-01-17 |
Amgen Inc. |
Human lcat antigen binding proteins and their use in therapy
|
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
|
AU2013208007A1
(en)
|
2012-01-09 |
2014-07-31 |
The Scripps Research Institute |
Humanized antibodies with ultralong CDR3
|
|
EP2802603A4
(en)
|
2012-01-09 |
2015-11-04 |
Scripps Research Inst |
REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
|
|
US9512212B2
(en)
|
2012-01-11 |
2016-12-06 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
|
EA201491413A1
(ru)
|
2012-01-26 |
2015-03-31 |
Эмджен Инк. |
Полипептиды фактора роста и дифференцировки 15 (gdf-15)
|
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
|
SG11201404898RA
(en)
|
2012-02-17 |
2014-09-26 |
Siga Technologies Inc |
Antiviral drugs for treatment of arenavirus infection
|
|
JP6216766B2
(ja)
|
2012-03-29 |
2017-10-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ |
クリック核酸
|
|
EP2843051B1
(en)
|
2012-04-23 |
2018-06-06 |
GeneFrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
MX2014013407A
(es)
|
2012-05-22 |
2014-11-26 |
Hoffmann La Roche |
Dipiridilaminas sustituidas y uso de las mismas.
|
|
CN104718188B
(zh)
|
2012-05-22 |
2018-08-21 |
基因泰克公司 |
N-取代的苯甲酰胺类及其在治疗疼痛中的用途
|
|
AU2013285537B2
(en)
|
2012-07-02 |
2017-10-12 |
Medizinische Universitat Wien |
Complement split product C4d for the treatment of inflammatory conditions
|
|
RU2015103913A
(ru)
|
2012-07-06 |
2016-08-27 |
Дженентек, Инк. |
N-замещенные бензамиды и способы их применение
|
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
|
US9119858B2
(en)
|
2012-08-21 |
2015-09-01 |
Genesys Research Institute, Inc. |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
|
MX2015003565A
(es)
|
2012-09-27 |
2015-06-22 |
Hoffmann La Roche |
Compuestos de sulfanamida sustituidos.
|
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
|
ES2703913T3
(es)
|
2012-10-17 |
2019-03-13 |
Vascular Biogenics Ltd |
Métodos de tratamiento que emplean adenovirus
|
|
CN104937099B
(zh)
|
2012-11-09 |
2018-03-30 |
基因先端领域株式会社 |
用于治疗癌症的抗adam28抗体
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
BR112015012644A2
(pt)
|
2012-11-30 |
2017-12-19 |
Hoffmann La Roche |
método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
WO2014111496A1
(en)
|
2013-01-18 |
2014-07-24 |
F. Hoffmann-La Roche Ag |
3-substituted pyrazoles and use as dlk inhibitors
|
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
US20140271629A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
|
WO2014153037A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Substituted triazolopyridines and methods of use thereof
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
|
US9676851B2
(en)
|
2013-03-15 |
2017-06-13 |
Amgen Inc. |
Human PAC1 antibodies
|
|
WO2014151834A2
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
|
EP2968480B1
(en)
|
2013-03-15 |
2020-10-14 |
Amgen Inc. |
Treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
|
|
EP2970449B1
(en)
|
2013-03-15 |
2019-09-25 |
Amgen Research (Munich) GmbH |
Single chain binding molecules comprising n-terminal abp
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
|
MA38624A1
(fr)
|
2013-05-01 |
2017-02-28 |
Hoffmann La Roche |
Composés bihétéroaryle et leurs utilisations
|
|
JP6523251B2
(ja)
|
2013-05-01 |
2019-05-29 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途
|
|
US10501803B2
(en)
|
2013-05-21 |
2019-12-10 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
|
JP6568052B2
(ja)
|
2013-05-22 |
2019-09-04 |
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． |
心不全を治療するためのニューレグリンの徐放
|
|
WO2014193800A2
(en)
|
2013-05-28 |
2014-12-04 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
|
KR102258460B1
(ko)
|
2013-05-30 |
2021-06-02 |
키닉사 파마슈티컬스, 리미티드 |
온코스타틴 m 수용체 항원 결합 단백질
|
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
EP3019531A4
(en)
|
2013-07-11 |
2017-03-15 |
The California Institute for Biomedical Research |
Immunoglobulin fusion proteins and compositions thereof
|
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
DK3027642T3
(da)
|
2013-07-31 |
2020-11-02 |
Amgen Inc |
Vækstdifferentieringsfaktor 15 (gdf-15)-konstruktioner
|
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
AU2014318748B2
(en)
|
2013-09-11 |
2019-02-28 |
Duquesne University Of The Holy Ghost |
Novel anthranilic amides and the use thereof
|
|
KR102302634B1
(ko)
|
2013-09-13 |
2021-09-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제 및 이의 조성물
|
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
|
|
DK3020727T4
(da)
|
2013-09-16 |
2021-04-19 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Mutant calreticulin til diagnose af myeloide maligniteter
|
|
WO2015041310A1
(ja)
|
2013-09-20 |
2015-03-26 |
中外製薬株式会社 |
抗プロテインｃ抗体による出血性疾患の治療
|
|
EP3521431A1
(en)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
|
EP3650023A1
(en)
|
2013-10-04 |
2020-05-13 |
Aptose Biosciences Inc. |
Compositions for treating cancers
|
|
RS58376B1
(sr)
|
2013-10-11 |
2019-04-30 |
Hoffmann La Roche |
Supstituisana heterociklična sulfonamidna jedinjenja korisna kao modulatori trpa1
|
|
JP6734774B2
(ja)
|
2013-10-15 |
2020-08-05 |
ザ スクリプス リサーチ インスティテュート |
ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用
|
|
SMT202400288T1
(it)
|
2013-10-15 |
2024-09-16 |
Genefrontier Corp |
Anticorpo umano contro specie di adamts di tipo aggrecanasi per terapia di malattie correlate ad aggrecanasi
|
|
US20150238631A1
(en)
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
|
DK3063275T3
(da)
|
2013-10-31 |
2019-11-25 |
Resolve Therapeutics Llc |
Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
|
|
KR102455171B1
(ko)
|
2013-12-18 |
2022-10-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
|
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
|
US10189908B2
(en)
|
2014-02-05 |
2019-01-29 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
|
|
EP3104873B1
(en)
|
2014-02-13 |
2019-09-04 |
Technische Universität München |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
|
SG11201606842RA
(en)
|
2014-02-20 |
2016-09-29 |
Allergan Inc |
Complement component c5 antibodies
|
|
RU2673036C2
(ru)
|
2014-02-27 |
2018-11-21 |
Аллерган, Инк. |
АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
|
|
WO2015134973A1
(en)
|
2014-03-07 |
2015-09-11 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
|
EP3143143A1
(en)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonists of slc38a9 and their use in therapy
|
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
|
US11357748B2
(en)
|
2014-05-30 |
2022-06-14 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
|
WO2015187779A1
(en)
|
2014-06-03 |
2015-12-10 |
Xbiotech, Inc. |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
|
JP6808493B2
(ja)
|
2014-06-09 |
2021-01-06 |
ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． |
最適な骨形成のための血清リンの効果的かつ効率的な制御
|
|
PE20170471A1
(es)
|
2014-06-13 |
2017-05-14 |
Santa Maria Biotherapeutics Inc |
Polipeptidos receptores formulados y metodos relacionados
|
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
|
|
WO2016007534A1
(en)
|
2014-07-07 |
2016-01-14 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
WO2016007919A2
(en)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
AU2015301753B2
(en)
|
2014-08-12 |
2021-04-08 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
|
|
US20170224777A1
(en)
|
2014-08-12 |
2017-08-10 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
JP6683686B2
(ja)
|
2014-08-22 |
2020-04-22 |
オークランド ユニサービシーズ リミティド |
チャネル調節剤
|
|
BR112017003986A2
(pt)
|
2014-08-27 |
2018-02-27 |
Peptimed Inc |
composições e métodos anti-tumor
|
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
|
CA2962451C
(en)
|
2014-10-21 |
2023-01-17 |
Sciclone Pharmaceuticals, Inc. |
Treatment of cancer with immune stimulators
|
|
EP3209316A2
(en)
|
2014-10-24 |
2017-08-30 |
Bristol-Myers Squibb Company |
Modified fgf-21 polypeptides and uses thereof
|
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
|
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
RU2722832C2
(ru)
|
2015-02-23 |
2020-06-04 |
Сигалл Терапьютикс Сас |
Неприродные семафорины класса 3 и их медицинское применение
|
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
CA2972393A1
(en)
|
2015-02-27 |
2016-09-01 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating il-6-related diseases
|
|
JP6701225B2
(ja)
|
2015-03-09 |
2020-05-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
三環式ｄｌｋ阻害剤及びその使用
|
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
|
CR20170510A
(es)
|
2015-04-10 |
2018-02-26 |
Amgen Inc |
Muteínas de interuquina 2 para la expansión de células t regulatorias
|
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
JP6907124B2
(ja)
|
2015-04-17 |
2021-07-21 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ |
Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
|
|
EP3285753A1
(en)
|
2015-04-22 |
2018-02-28 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
|
EP3294072A4
(en)
*
|
2015-05-15 |
2019-03-13 |
The Johns Hopkins University |
NOVEL PRENATAL FOOD SUPPLEMENT WITH FLUORIDE
|
|
CA2986045A1
(en)
|
2015-05-22 |
2016-12-01 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
|
CN107921098A
(zh)
|
2015-06-17 |
2018-04-17 |
加州生物医学研究所 |
修饰的治疗剂及其组合物
|
|
EP3319613B1
(en)
|
2015-07-07 |
2023-02-22 |
The Research Foundation for The State University of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
|
EP3328374A4
(en)
|
2015-07-31 |
2019-03-13 |
The Johns Hopkins University |
GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
|
|
SI3328827T1
(sl)
|
2015-07-31 |
2023-11-30 |
The Johns Hopkins University |
Predzdravila glutamin analogov
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
|
WO2017023787A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Methods and compositions for treating metabolic reprogramming disorders
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
WO2017035271A1
(en)
|
2015-08-27 |
2017-03-02 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
JP6951825B2
(ja)
|
2015-09-04 |
2021-10-20 |
ザ スクリプス リサーチ インスティテュート |
インスリン免疫グロブリン融合タンパク質
|
|
JP2018529729A
(ja)
|
2015-10-01 |
2018-10-11 |
アムジエン・インコーポレーテツド |
胆汁酸障害の処置
|
|
JP2019503985A
(ja)
|
2015-11-03 |
2019-02-14 |
グリコミメティクス， インコーポレイテッド |
モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
|
|
CA3004048A1
(en)
|
2015-11-03 |
2017-05-11 |
Regents Of The University Of Minnesota |
Cd200 inhibitors and methods of use thereof
|
|
BR112018009550A2
(pt)
|
2015-11-13 |
2018-11-06 |
Mavalon Therapeutics Ltd |
derivados de 1,4-benzodiazepinona tricíclica substituída como moduladores alostéricos de receptores de glutamato metabotrópico de grupo ii
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
|
|
JP2018535234A
(ja)
|
2015-11-25 |
2018-11-29 |
ジェネンテック， インコーポレイテッド |
ナトリウムチャネル遮断薬として有用な置換ベンズアミド
|
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
|
SG11201804885TA
(en)
|
2015-12-09 |
2018-07-30 |
Univ Wien Med |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
|
EP4011919A3
(en)
|
2015-12-09 |
2022-10-12 |
The Scripps Research Institute |
Relaxin immunoglobulin fusion proteins and methods of use
|
|
CN117106085A
(zh)
|
2015-12-23 |
2023-11-24 |
美国安进公司 |
使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
|
|
EP3395835B1
(en)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
|
WO2017121855A1
(en)
|
2016-01-15 |
2017-07-20 |
Universität Hamburg |
Flavonoide-type compounds bearing an o-rhamnosyl residue
|
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究（慕尼黑）公司 |
包含雙特異性抗體建構物之醫藥組合物
|
|
MY195542A
(en)
|
2016-02-03 |
2023-01-31 |
Amgen Res Munich Gmbh |
Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
WO2017134134A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
|
EP4299072A3
(en)
|
2016-02-10 |
2024-05-01 |
Rutgers, the State University of New Jersey |
Novel anti-lam antibodies
|
|
CA3013988A1
(en)
|
2016-02-15 |
2017-08-24 |
Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh |
Taf1 inhibitors for the therapy of cancer
|
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
|
AU2017233658B2
(en)
|
2016-03-14 |
2023-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
|
JP2019513714A
(ja)
|
2016-03-30 |
2019-05-30 |
ジェネンテック， インコーポレイテッド |
置換ベンズアミド及びその使用方法
|
|
ES2957548T3
(es)
|
2016-04-15 |
2024-01-22 |
Univ Oxford Innovation Ltd |
Moduladores del receptor de adenosina para el tratamiento de los trastornos del ritmo circadiano
|
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
WO2018013924A1
(en)
|
2016-07-15 |
2018-01-18 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
|
WO2018015410A1
(en)
|
2016-07-20 |
2018-01-25 |
F. Hoffmann-La Roche Ag |
Bicyclic proline compounds
|
|
JP6975515B2
(ja)
|
2016-07-20 |
2021-12-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
|
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
|
WO2018024654A1
(en)
|
2016-08-02 |
2018-02-08 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
|
KR20190037261A
(ko)
|
2016-08-08 |
2019-04-05 |
암젠 인크 |
항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
|
|
WO2018029288A1
(en)
|
2016-08-12 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Sulfonyl pyridyl trp inhibitors
|
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
|
AU2017325240B9
(en)
|
2016-09-06 |
2025-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
|
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
|
MX2019000735A
(es)
|
2016-09-16 |
2019-12-02 |
Res Triangle Inst |
Antagonistas opioides kappa de tetrahidroisoquinolina.
|
|
JP7349359B2
(ja)
|
2016-10-17 |
2023-09-22 |
エフ． ホフマン－ラ ロシュ アーゲー |
二環式ピリドンラクタム及びその使用方法。
|
|
CN110267982B
(zh)
|
2016-10-19 |
2024-02-23 |
斯克利普斯研究所 |
具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
|
|
MX2019005443A
(es)
|
2016-11-14 |
2019-11-21 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
|
|
CN110225911B
(zh)
|
2016-11-28 |
2022-04-05 |
豪夫迈·罗氏有限公司 |
噁二唑酮瞬时受体电位通道抑制剂
|
|
MA46937A
(fr)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center For Personalized Cancer Medicine Gmbh |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines
|
|
JP6890179B2
(ja)
|
2016-12-02 |
2021-06-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
二環式アミド化合物及びその使用方法
|
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
|
CA3049110A1
(en)
|
2017-01-06 |
2018-07-12 |
Abl Bio Inc. |
Anti-.alpha.-syn antibody and use thereof
|
|
MX2019008029A
(es)
|
2017-01-06 |
2019-12-11 |
Abl Bio Inc |
Anticuerpo anti-alfa-sinucleina y su uso.
|
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
|
CA3049656A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
|
EP4364799A3
(en)
|
2017-01-11 |
2024-07-17 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Mesenchymal stem cell-derived extracellular vesicles and their medical use
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
US10266578B2
(en)
|
2017-02-08 |
2019-04-23 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
|
WO2018160791A1
(en)
|
2017-03-03 |
2018-09-07 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
|
CN110461838B
(zh)
|
2017-03-07 |
2022-05-06 |
豪夫迈·罗氏有限公司 |
噁二唑瞬时受体电位通道抑制剂
|
|
EP3601273B1
(en)
|
2017-03-24 |
2021-12-01 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
|
MX2019013142A
(es)
|
2017-05-05 |
2019-12-16 |
Amgen Inc |
Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
|
|
US11472806B2
(en)
|
2017-05-12 |
2022-10-18 |
Domain Therapeutics |
Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
|
|
AU2018265584B2
(en)
|
2017-05-12 |
2023-09-28 |
Ludwig-Maximilians-Universität München |
Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
|
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
AU2018288854A1
(en)
|
2017-06-20 |
2019-11-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
UA125448C2
(uk)
|
2017-07-14 |
2022-03-09 |
Ф. Хоффманн-Ля Рош Аг |
Біциклічні кетонові сполуки і способи їх застосування
|
|
WO2019018691A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
MODULATION OF CYTOKINE
|
|
EP3665202A1
(en)
|
2017-08-09 |
2020-06-17 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
|
EP3672986A1
(en)
|
2017-08-22 |
2020-07-01 |
Sanabio, LLC |
Soluble interferon receptors and uses thereof
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
WO2019070901A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
IMMUNOGLOBULIN FUSIONS OF TRANSTHYRETIN
|
|
PE20211246A1
(es)
|
2017-10-11 |
2021-07-13 |
Hoffmann La Roche |
Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
|
|
EP3698808B1
(en)
|
2017-10-20 |
2025-01-01 |
Hyogo College Of Medicine |
Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
|
MA50536A
(fr)
|
2017-10-30 |
2020-09-09 |
Enterin Inc |
Nouvelles formes solides de squalamine et procédés pour les produire
|
|
PE20211247A1
(es)
|
2017-10-31 |
2021-07-13 |
Hoffmann La Roche |
Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
|
AU2018383679A1
(en)
|
2017-12-11 |
2020-05-07 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
WO2019117685A2
(ko)
|
2017-12-14 |
2019-06-20 |
에이비엘바이오 주식회사 |
항-igf1r 항체 및 그 용도
|
|
KR20200101954A
(ko)
|
2017-12-19 |
2020-08-28 |
메사추세츠 인스티튜트 오브 테크놀로지 |
항원-아주반트 커플링 시약 및 사용 방법
|
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
WO2019151418A1
(ja)
|
2018-01-31 |
2019-08-08 |
元一 加藤 |
Ｉｌ－６阻害剤を含有する喘息の治療剤
|
|
SG11202007558YA
(en)
|
2018-02-09 |
2020-09-29 |
Nestle Skin Health Sa |
Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
|
|
AR114585A1
(es)
|
2018-02-20 |
2020-09-23 |
Hoffmann La Roche |
Proceso para preparar compuestos antagonistas de canales potenciales transitorios del receptor de 1-arilsulfonil-pirrolidin-2-carboxamida y formas cristalinas de los mismos
|
|
CN112041313A
(zh)
|
2018-02-26 |
2020-12-04 |
基因泰克公司 |
吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途
|
|
NZ767596A
(en)
|
2018-03-14 |
2022-01-28 |
Surface Oncology Inc |
Antibodies that bind cd39 and uses thereof
|
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
|
US11332524B2
(en)
|
2018-03-22 |
2022-05-17 |
Surface Oncology, Inc. |
Anti-IL-27 antibodies and uses thereof
|
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
WO2019191534A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
|
BR112020020464A2
(pt)
|
2018-04-06 |
2021-01-12 |
Zilentin AG |
Derivados de bumetanida para a terapia da hiperidrose
|
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
|
CN111954537A
(zh)
|
2018-04-09 |
2020-11-17 |
美国安进公司 |
生长分化因子15融合蛋白
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
CN112105733B
(zh)
|
2018-04-19 |
2024-10-29 |
查美特制药公司 |
合成rig-i样受体激动剂
|
|
JP7398391B2
(ja)
|
2018-04-20 |
2023-12-14 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
|
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
|
TW202003580A
(zh)
|
2018-05-21 |
2020-01-16 |
美商坎伯斯治療有限責任公司 |
用於增強nk細胞對標靶細胞之殺死之組合物及方法
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
WO2019225777A1
(ko)
|
2018-05-23 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-ror1 항체 및 그 용도
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
WO2020011938A1
(en)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoids for the topical treatment of autoimmune gastritis
|
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
JP2021535140A
(ja)
|
2018-08-28 |
2021-12-16 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
抗ｃｄ３抗体葉酸生物複合体およびその使用
|
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
|
CN116948006A
(zh)
|
2018-09-11 |
2023-10-27 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其用途
|
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
|
WO2020068261A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020077212A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
|
US20220009986A1
(en)
|
2018-10-19 |
2022-01-13 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
|
AU2019407650B2
(en)
|
2018-12-17 |
2022-10-27 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
|
CN113597319A
(zh)
|
2019-01-04 |
2021-11-02 |
分解治疗有限责任公司 |
用核酸酶融合蛋白治疗干燥症
|
|
JP7585205B2
(ja)
|
2019-01-11 |
2024-11-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式ピロロトリアゾールケトン化合物及びその使用方法
|
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
|
US20220226488A1
(en)
|
2019-02-12 |
2022-07-21 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
|
WO2020191305A2
(en)
|
2019-03-20 |
2020-09-24 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
|
US20220220210A1
(en)
|
2019-03-29 |
2022-07-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
|
|
MX2021012163A
(es)
|
2019-04-17 |
2022-01-31 |
Univ Hiroshima |
Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
|
|
WO2020241816A1
(ja)
|
2019-05-31 |
2020-12-03 |
国立大学法人大阪大学 |
新規な消化器がん治療剤およびそのスクリーニング方法
|
|
CA3142676A1
(en)
|
2019-06-05 |
2020-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site binding molecule
|
|
MA56131A
(fr)
|
2019-06-10 |
2022-04-13 |
Chugai Pharmaceutical Co Ltd |
Molécule de liaison à l'antigène anti-lymphocytes t à utiliser en association avec un inhibiteur de cytokines
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
KR20220032065A
(ko)
|
2019-07-08 |
2022-03-15 |
암젠 인크 |
다중특이성 트랜스타이레틴 면역글로불린 융합
|
|
PE20220392A1
(es)
|
2019-07-10 |
2022-03-18 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union a claudina-6 y usos de las mismas
|
|
AU2020323901A1
(en)
|
2019-07-26 |
2022-02-24 |
Amgen Inc. |
Anti-IL13 antigen binding proteins
|
|
MX2022001732A
(es)
|
2019-08-12 |
2022-05-06 |
Purinomia Biotech Inc |
Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
|
|
JP2022544236A
(ja)
|
2019-08-13 |
2022-10-17 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
AU2020351122A1
(en)
|
2019-09-16 |
2022-02-17 |
Surface Oncology, Inc. |
Anti-CD39 antibody compositions and methods
|
|
BR112022004302A2
(pt)
|
2019-09-25 |
2022-06-21 |
Surface Oncology Inc |
Anticorpos anti-il-27 e usos dos mesmos
|
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
|
US20230064948A1
(en)
|
2019-10-02 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
WO2021070885A1
(ja)
|
2019-10-11 |
2021-04-15 |
中外製薬株式会社 |
後天性血友病ａの予防および／または治療に用いられる医薬組成物、および当該医薬組成物を含む製品
|
|
AU2020366135B2
(en)
|
2019-10-16 |
2024-12-12 |
Proxygen Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2021081353A1
(en)
|
2019-10-23 |
2021-04-29 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
EP4048405A2
(en)
|
2019-10-24 |
2022-08-31 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
|
AU2020381458A1
(en)
|
2019-11-13 |
2022-05-12 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN114728927A
(zh)
|
2019-11-19 |
2022-07-08 |
莫达戈有限公司 |
用于诊断、治疗和预防与α-突触核蛋白的聚集相关的疾病的新颖化合物
|
|
WO2021127262A1
(en)
|
2019-12-17 |
2021-06-24 |
Amgen Inc. |
Dual interleukin-2 /tnf receptor agonist for use in therapy
|
|
NZ788662A
(en)
|
2020-01-06 |
2024-11-29 |
Vaccinex Inc |
Anti-ccr8 antibodies and uses thereof
|
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
|
CA3174114A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
|
BR112022018111A2
(pt)
|
2020-03-19 |
2022-10-25 |
Amgen Inc |
Anticorpos contra mucina 17 e usos dos mesmos
|
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
EP4161520A1
(en)
|
2020-06-05 |
2023-04-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
BR112022025536A2
(pt)
|
2020-06-19 |
2023-01-17 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação ao antígeno de células anti-t para uso em combinação com o inibidor da angiogênese
|
|
MX2022016497A
(es)
|
2020-06-25 |
2023-01-30 |
Tolremo Therapeutics Ag |
Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica.
|
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
|
BR112023000537A2
(pt)
|
2020-07-31 |
2023-01-31 |
Chugai Pharmaceutical Co Ltd |
Composições farmacêuticas incluindo célula que expressa o receptor quimérico
|
|
TW202227449A
(zh)
|
2020-08-20 |
2022-07-16 |
美商Ａｍｂｒｘ 公司 |
抗體－ｔｌｒ促效劑偶聯物、其方法及用途
|
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
|
MX2023003759A
(es)
|
2020-10-02 |
2023-04-24 |
Genentech Inc |
Proceso para la preparacion de compuestos de biheteroarilo y formas cristalinas de estos.
|
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
|
AU2021374839A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
US20240228593A9
(en)
|
2021-02-19 |
2024-07-11 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
|
|
TW202302143A
(zh)
|
2021-03-12 |
2023-01-16 |
日商中外製藥股份有限公司 |
重症肌無力症之治療或預防用之醫藥組合物
|
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
JP2024515061A
(ja)
|
2021-04-07 |
2024-04-04 |
トルレモ・セラピューティクス・アクチェンゲゼルシャフト |
複素環誘導体、医薬組成物およびがんの治療または軽快におけるこれらの使用
|
|
CN118251420A
(zh)
|
2021-04-28 |
2024-06-25 |
米诺陶治疗公司 |
人源化嵌合牛抗体和使用方法
|
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
|
IL308496A
(en)
|
2021-05-14 |
2024-01-01 |
Claris Biotherapeutics Inc |
Growth factor compounds for the treatment of eye diseases
|
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
|
AU2022337073A1
(en)
|
2021-08-30 |
2024-04-11 |
Chugai Seiyaku Kabushiki Kaisha |
Treatments for atopic dermatitis
|
|
WO2023031881A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long qt syndrome
|
|
JPWO2023053282A1
(da)
|
2021-09-29 |
2023-04-06 |
|
|
|
EP4426433A1
(en)
|
2021-11-03 |
2024-09-11 |
Affimed GmbH |
Bispecific cd16a binders
|
|
MX2024005106A
(es)
|
2021-11-03 |
2024-07-02 |
Affimed Gmbh |
Ligandos biespecificos de cd16a.
|
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
AU2023255339A1
(en)
|
2022-04-19 |
2024-12-05 |
Sasha A. PHILBERT |
Treatment of brain copper disorders
|
|
WO2023203174A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
|
CN119137147A
(zh)
|
2022-05-12 |
2024-12-13 |
安进研发（慕尼黑）股份有限公司 |
具有增加的选择性的多链多靶向性双特异性抗原结合分子
|
|
WO2023230116A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
WO2023243689A1
(ja)
|
2022-06-16 |
2023-12-21 |
国立大学法人大阪大学 |
新規な炎症性疾患治療剤およびそのスクリーニング方法
|
|
US20240141050A1
(en)
|
2022-09-02 |
2024-05-02 |
Galderma Holding S.A. |
Treatments for prurigo nodularis
|
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|
|
WO2024121796A1
(en)
|
2022-12-07 |
2024-06-13 |
Fondazione Matilde Tettamanti E Menotti De Marchi Onlus |
Methods for generating genetically modified cytokine induced killer (cik) cells
|
|
WO2025006676A2
(en)
|
2023-06-27 |
2025-01-02 |
Firecyte Therapeutics, Inc. |
Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
|